| Literature DB >> 27677355 |
Xiefan Fang1, Ryan R Poulsen1, Scott A Rivkees1, Christopher C Wendler1.
Abstract
Each year millions of pregnant woman are exposed to caffeine, which acts to antagonize adenosine action. The long-term consequences of this exposure on the developing fetus are largely unknown, although in animal models we have found adverse effects on cardiac function. To assess if these effects are transmitted transgenerationally, we exposed pregnant mice to caffeine equivalent to 2-4 cups of coffee at two embryonic stages. Embryos (F1 generation) exposed to caffeine early from embryonic (E) day 6.5-9.5 developed a phenotype similar to dilated cardiomyopathy by 1 year of age. Embryos exposed to caffeine later (E10.5-13.5) were not affected. We next examined the F2 generation and F3 generation of mice exposed to caffeine from E10.5-13.5, as this coincides with germ cell development. These F2 generation adult mice developed a cardiac phenotype similar to hypertrophic cardiomyopathy. The F3 generation exhibited morphological changes in adult hearts, including increased mass. This report shows that in utero caffeine exposure has long-term effects into adulthood and that prenatal caffeine exposure can exert adverse transgenerational effects on adult cardiac function.Entities:
Year: 2016 PMID: 27677355 PMCID: PMC5039698 DOI: 10.1038/srep34106
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Echocardiography analysis of adult F1 generation mice exposed to caffeine or vehicle as embryos in utero from E6.5–9.5.
| Treatment | Age | IVS;d | LVID;d | LVPW;d | LV Vol;d | IVS;s | LVID;s | LVPW;s | LV Vol;s | % EF | % FS | LV Mass | Heart Rate | Weight | N |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E6.5–9.5 | mm | mm | mm | ul | mm | mm | mm | ul | % | % | mg | BPM | g | ||
| Vehicle | 0.74 | 4.77 | 0.84 | 106.50 | 1.01 | 3.56 | 1.17 | 53.69 | 49.90 | 25.53 | 124.70 | 481.57 | 39.85 | 4 | |
| Caffeine | 0.80 | 4.60 | 0.89 | 97.92 | 1.10 | 3.29 | 1.23 | 45.23 | 54.76 | 28.69 | 128.07 | 475.44 | 42.98 | 4 | |
| P-value | 0.07 | 0.08 | 0.18 | 0.08 | 0.10 | 0.06 | 0.24 | 0.09 | 0.09 | 0.08 | 0.36 | 0.42 | 0.08 | ||
| E6.5–9.5 | |||||||||||||||
| Vehicle | 0.84 | 4.63 | 0.93 | 98.97 | 1.15 | 3.25 | 1.30 | 43.26 | 56.58 | 29.81 | 137.03 | 503.31 | 53.54 | 3 | |
| Caffeine | 0.92 | 4.81 | 0.92 | 108.31 | 1.25 | 3.50 | 1.26 | 51.65 | 52.72 | 27.35 | 154.51 | 499.41 | 53.86 | 4 | |
| P-value | 0.02 | 0.01 | 0.46 | 0.01 | 0.06 | 0.04 | 0.28 | 0.05 | 0.14 | 0.15 | 0.04 | 0.45 | 0.46 | ||
| E6.5–9.5 | |||||||||||||||
| Vehicle | 0.95 | 4.68 | 1.07 | 102.53 | 1.33 | 3.30 | 1.49 | 44.87 | 56.47 | 29.66 | 169.77 | 495.54 | 62.13 | 4 | |
| Caffeine | 0.96 | 4.94 | 1.06 | 115.91 | 1.30 | 3.70 | 1.32 | 59.77 | 48.89 | 25.28 | 183.34 | 469.46 | 59.36 | 4 | |
| P-value | 0.45 | 0.11 | 0.42 | 0.12 | 0.35 | 0.04 | 0.02 | 0.04 | 0.02 | 0.02 | 0.26 | 0.18 | 0.34 | ||
IVS, interventricular septum; LVID, left ventricle internal diameter; LVPW, left ventricular posterior wall; LV, left ventricle; FS, fraction shortening; Vol, volume; EF, ejection fraction; d, diastole; s, systole. Units: IVS, LVID, LVPW are measured in millimeters (mm); LV vol is measured in milliliters (ml); LV mass is measured in milligrams (mg). *P-value ≤ 0.05. P-values were calculated by Student’s t-test.
Echocardiography analysis of F1, F2, and F3 generation adult offspring of F0 dams exposed to vehicle or caffeine.
| Age/Generation | IVS;d | LVID;d | LVPW;d | LV Vol;d | IVS;s | LVID;s | LVPW;s | LV Vol;s | % EF | % FS | LV Mass | Heart Rate | Weight | N | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E10.5-13.5 | mm | mm | mm | ul | mm | mm | mm | ul | % | % | mg | BPM | g | ||
| Vehicle | 1.00 | 4.47 | 0.94 | 92.01 | 1.37 | 3.24 | 1.24 | 43.55 | 53.71 | 28.02 | 147.37 | 521.75 | 50.83 | 5 | |
| Caffeine | 0.94 | 4.61 | 0.98 | 99.24 | 1.26 | 3.49 | 1.24 | 52.95 | 47.11 | 24.11 | 150.62 | 493.81 | 50.97 | 4 | |
| P-value | 0.21 | 0.25 | 0.11 | 0.21 | 0.14 | 0.20 | 0.50 | 0.16 | 0.15 | 0.16 | 0.42 | 0.16 | 0.49 | ||
| E10.5-13.5 | |||||||||||||||
| Vehicle | 1.03 | 4.58 | 0.98 | 96.47 | 1.34 | 3.26 | 1.34 | 43.46 | 55.47 | 28.94 | 157.57 | 496.03 | 52.51 | 5 | |
| Caffeine | 0.90 | 4.84 | 1.01 | 110.90 | 1.25 | 3.49 | 1.38 | 52.46 | 54.03 | 28.19 | 164.50 | 473.44 | 61.33 | 4 | |
| P-value | 0.08 | 0.14 | 0.27 | 0.13 | 0.16 | 0.21 | 0.29 | 0.20 | 0.37 | 0.39 | 0.32 | 0.15 | 0.08 | ||
| E10.5–13.5 | |||||||||||||||
| Vehicle | 0.88 | 4.62 | 0.94 | 98.84 | 1.21 | 3.36 | 1.25 | 46.72 | 53.01 | 27.42 | 142.55 | 494.17 | 52.16 | 5 | |
| Caffeine | 0.84 | 4.59 | 0.95 | 97.20 | 1.16 | 3.29 | 1.29 | 44.35 | 54.29 | 28.36 | 137.13 | 471.52 | 50.06 | 4 | |
| P-value | 0.23 | 0.42 | 0.48 | 0.41 | 0.23 | 0.31 | 0.33 | 0.32 | 0.37 | 0.36 | 0.28 | 0.20 | 0.30 | ||
| E10.5–13.5 | |||||||||||||||
| Vehicle | 0.92 | 5.00 | 1.00 | 118.72 | 1.29 | 3.66 | 1.34 | 57.24 | 52.09 | 26.89 | 173.76 | 523.84 | 60.10 | 5 | |
| Caffeine | 0.89 | 4.75 | 1.11 | 105.32 | 1.25 | 3.32 | 1.50 | 45.54 | 57.01 | 30.07 | 169.31 | 526.52 | 59.62 | 7 | |
| P-value | 0.22 | 0.03 | 0.01 | 0.03 | 0.24 | 0.02 | 0.01 | 0.02 | 0.04 | 0.04 | 0.33 | 0.44 | 0.47 | ||
| E10.5–13.5 | |||||||||||||||
| Vehicle | 0.92 | 4.60 | 0.94 | 97.37 | 1.28 | 3.32 | 1.25 | 45.24 | 53.67 | 27.75 | 145.25 | 518.58 | 51.71 | 5 | |
| Caffeine | 0.92 | 4.77 | 0.96 | 106.35 | 1.28 | 3.40 | 1.33 | 48.24 | 54.95 | 28.66 | 157.30 | 498.39 | 51.35 | 4 | |
| P-value | 0.31 | 0.09 | 0.04 | 0.09 | 0.37 | 0.33 | 0.01 | 0.31 | 0.23 | 0.21 | 0.05 | 0.39 | 0.31 | ||
| E10.5–13.5 | |||||||||||||||
| Vehicle | 1.00 | 4.70 | 1.06 | 102.75 | 1.42 | 3.28 | 1.48 | 44.50 | 57.26 | 30.39 | 174.27 | 554.53 | 62.73 | 5 | |
| Caffeine | 0.95 | 5.07 | 1.15 | 125.27 | 1.42 | 3.28 | 1.48 | 67.29 | 49.37 | 25.72 | 201.70 | 552.16 | 63.04 | 4 | |
| P-value | 0.26 | 0.18 | 0.08 | 0.15 | 0.27 | 0.20 | 0.16 | 0.18 | 0.26 | 0.28 | 0.04 | 0.44 | 0.35 | ||
Only the F1 generation embryos were exposed to vehicle or caffeine in utero from E10.5-13.5. For abbreviations please see Table 1. *P-value ≤ 0.05. P-values were calculated by Student’s t-test.
Echocardiography analysis 20 minutes after dobutamine treatment of CD-1 mice exposed to caffeine or vehicle in utero from E6.5–9.5.
| Treatment | IVS;d | LVID;d | LVPW;d | LV Vol;d | IVS;s | LVID;s | LVPW;s | LV Vol;s | % EF | % FS | LV Mass | Heart Rate | N | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E6.5–9.5 | mm | mm | mm | ul | mm | mm | mm | ul | % | % | mg | BPM | ||
| Vehicle | 0.82 | 4.22 | 0.99 | 80.06 | 1.35 | 2.35 | 1.63 | 20.62 | 75.31 | 44.59 | 122.21 | 489.36 | 4 | |
| Caffeine | 0.89 | 4.03 | 1.02 | 71.98 | 1.42 | 2.21 | 1.58 | 17.54 | 76.68 | 45.67 | 121.04 | 503.48 | 4 | |
| P-value | 0.01 | 0.09 | 0.31 | 0.08 | 0.07 | 0.15 | 0.33 | 0.14 | 0.29 | 0.31 | 0.43 | 0.17 | ||
| E6.5–9.5 | ||||||||||||||
| Vehicle | 0.92 | 4.25 | 1.09 | 81.43 | 1.59 | 2.11 | 1.78 | 15.38 | 81.65 | 50.53 | 142.17 | 485.50 | 3 | |
| Caffeine | 0.95 | 4.15 | 0.99 | 77.45 | 1.45 | 2.44 | 1.54 | 22.24 | 72.42 | 41.53 | 130.98 | 529.10 | 3 | |
| P-value | 0.15 | 0.33 | 0.01 | 0.35 | 0.01 | 0.12 | 0.001 | 0.15 | 0.03 | 0.02 | 0.20 | 0.01 | ||
For abbreviations please see Table 1. *P-value ≤ 0.05. P-values were calculated by Student’s t-test.
Figure 1M-mode measurements before and after dobutamine treatment in 22 week old mice.
For this analysis F1 generation mice from dams treated with vehicle or caffeine from E6.5–9.5 were used. Baseline echocardiograms were taken of (A) vehicle- and (C) caffeine-treated mice. 20 minutes after dobutamine another set of echocardiograms were taken of (B) vehicle- and (D) caffeine-treated mice. Data indicate that caffeine-exposed hearts have impaired response to β-adrenergic stimulation during systole and diastole. Measurements that were altered include interventricular septum (IVS;s); left ventricular posterior wall (LVPW;s, d); d, diastole; s, systole. N = 3–4, P ≤ 0.05. Scale bar = 1 mm.
Figure 2In utero caffeine exposure leads to altered cardiac gene expression in the F1 generation at 1 year of age.
Early in utero exposure to caffeine from E6.5–9.5 caused increased RNA expression of Myh7, ANP, Mef2c, and Nfatc-1A in the left ventricle. Late in utero exposure from E10.5–13.5 caused altered expression of Tnni3, ANP, Mef2d, and Nfatc1-C. Fold change in gene expression between vehicle and caffeine treated mice was calculated with the 2−∆∆CT method using Gapdh as the control gene. Significance was determined by Student’s t-test and a P ≤ 0.05 was determined to be significant. N = 4, *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001.
Figure 3In utero caffeine exposure leads to altered cardiac gene expression in F2 and F3 generation at 1 year of age.
qPCR analysis revealed that in utero caffeine treatment during E10.5–13.5 altered gene expression in the left ventricles of F2 generation offspring, including Myh7, Tnni3, BNP, Tnnc1, and Camta1. In utero caffeine treatment during E10.5–13.5 increased Gata4 expression in the left ventricles of F3 generation offspring. Fold-change in gene expression between vehicle and caffeine treated mice was calculated with the 2−∆∆CT method using Gapdh as the control gene. Significance was determined by Student’s t-test and a P ≤ 0.05 was determined to be significant. N = 5, *P ≤ 0.05, **P ≤ 0.01.
Altered cellular morphology and function pathways in adult F1 mice treated with caffeine during E6.5–10.5.
| p-value | Activation z-score | # of molecules | |
|---|---|---|---|
| Cell death and survival | |||
| Cytolysis | 6.79E-04 | −1.034 | 7 |
| Proliferation of cells | 2.11E-03 | −0.513 | 37 |
| Cell death | 2.40E-03 | −0.323 | 34 |
| Cell morphology, cellular function and maintenance | |||
| Nucleation of filaments | 9.91E-04 | — | 3 |
| Cellular homeostasis | 3.38E-03 | 0.297 | 19 |
| Morphology of cells | 5.15E-03 | — | 22 |
| Generation of filaments | 6.22E-03 | — | 2 |
| Cell signaling | |||
| Activation of cells | 2.76E-05 | −0.500 | 18 |
| Quantity of Ca2+ | 8.31E-03 | −0.240 | 7 |
aA positive z-score means the pathway is activated, and a negative z-score indicates the pathway is inhibited.
Altered cardiovascular disease pathways in adult F1 mice treated with caffeine during E6.5–9.5.
| Pathways | p-value | Activation z-score | Genes |
|---|---|---|---|
| Infarction | 3.47E-06 | −2.750 | ACTA1,APOE,C1QA,CD55,FSTL1,GDF15,GPX1,HLA-A,PTGDS,STAT1,TNFRSF12A |
| Myocardial infarction | 8.08E-04 | −1.992 | ACTA1,APOE,CD55,FSTL1,GDF15,STAT1 |
| Permeability of vascular system | 8.44E-03 | −1.969 | APOE,AQP4,FGFBP3,TNFRSF12A |
| Size of infarct | 3.31E-06 | −1.673 | APOE,C1QA,GDF15,GPX1,HLA-A,PTGDS,STAT1,TNFRSF12A |
| Vasculogenesis | 6.05E-03 | −1.109 | ABRA,APOE,C1QA,GPX1,HLA-DQB1,KLK3,SEMA3B,STAT1,THBS4,TNFRSF12A,WARS |
| Adhesion of endothelial cells | 6.33E-03 | −0.293 | C1QA,CD274,GDF15,STAT1 |
| Lesioning of aorta | 9.10E-07 | APOE,GPX1,NPC1 | |
| Peripheral vascular disease | 8.48E-03 | APOE,AQP4,CFH,GPX1,MARK1,SEMA3B,TNFRSF12A | |
| Size of vascular lesion | 7.61E-03 | APOE,C1QA,GPX1 | |
| Advanced stage peripheral arterial disease | 6.89E-03 | APOE,CFH,MARK1,SEMA3B | |
| Thickness of heart ventricle | 6.70E-03 | APOE,KLK3 | |
| Cellularity of atherosclerotic lesion | 2.05E-05 | APOE,NPC1 | |
| Function of cardiovascular system | 1.18E-03 | ABRA,APOE,AQP4,CD55,CFP,GDF15,GPX1,KLK3 | |
| Thrombosis | 1.16E-02 | APOE,C1QA,CFH,GDF15 | |
| Mass of left ventricle | 1.05E-02 | KLK3,THBS4 |
aA positive z-score means the pathway is activated, and a negative z-score indicates the pathway is inhibited.
Figure 4Timing of in utero caffeine exposure leads to different cardiac phenotypes in adult offspring.
The timing of in utero caffeine treatment leads to differences in adult cardiac function, gene expression, and phenotype. Exposure to caffeine from E6.5–9.5 leads the F1 generation to develop dilated cardiomyopathy with decreased % FS and increased Myh7 expression. In utero caffeine exposure from E10.5–13.5 leads to a hypertrophic cardiomyopathy in the F2 generation along with increased % FS and decreased Myh7 expression.
Timing of analysis performed on F1 offspring exposed to vehicle or caffeine in utero from E6.5–9.5.
| Dam | F1 Offspring | ||
|---|---|---|---|
| Experimental Analysis | |||
| Treatment/Timing | 12 Weeks | 22 Weeks | 52 Weeks |
| Vehicle/E6.5–9.5 Caffeine/E6.5–9.5 | 1) Echocardiography | 1) Echocardiography | 1) Echocardiography |
| 2) Dobutamine Treatment | 2) Dobutamine Treatment | 2) Gene Expression | |
| 4) RNA Seq. | |||
| 5) Histology | |||
Timing of analysis performed on F1, F2, and F3 offspring exposed to vehicle or caffeine in utero from E10.5–13.5.
| Dam | F1 Offspring | F2 Offspring | F3 Offspring | |||
|---|---|---|---|---|---|---|
| Treatment/Timing | Analysis | Analysis | Analysis | |||
| 22 Weeks | 52 Weeks | 22 Weeks | 52 Weeks | 22 Weeks | 52 Weeks | |
| Vehicle/E10.5–13.5 Caffeine/E10.5–13.5 | 1) Echos | 1) Echos 2) Gene Expression 3) Histology | 1) Echos | 1) Echos 2) Gene Expression 3) Histology | 1) Echos | 1) Echos 2) Gene Expression 3) Histology |